GT Biopharma Announces GTB-3550 TriKE™ Monotherapy Rescues and Restores NK Cell Immune Surveillance in Relapsed/Refractory AML and MDS Cancer Patients

BEVERLY HILLS, Calif., April 12, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…

GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial

BEVERLY HILLS, Calif., April 8, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…

GT Biopharma’s TriKE™ Interim Clinical Trial Results Presented At Innate Killer Summit 2021

Outlines the Clinical Power of Immune Engagement with IL-15 Containing TriKEs BEVERLY…